Skip to content

Digital Angiography-Derived Fractional Flow Assessment for Intracranial Stenosis

Digital Angiography-Based Hemodynamic Assessment for Stroke Risk Stratification in Intracranial Arterial Stenosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07309705
Acronym
CASSISS-DPR
Enrollment
400
Registered
2025-12-30
Start date
2025-12-01
Completion date
2028-01-01
Last updated
2025-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodynamic, Intracranial Atherosclerosis ICAS, Stroke

Keywords

Intracranial Atherosclerotic Stenosis, Recurrent Stroke Risk, Hemodynamic Impairment, Fractional Flow Reserve, Precision Risk Stratification

Brief summary

The goal of this observational study is to learn whether a digital angiography derived fractional flow reserve (DPR) measurement can improve the prediction of stroke risk in adults with symptomatic intracranial atherosclerotic stenosis, defined as 50 to 99 percent narrowing. The main questions it aims to answer are: Does DPR identify patients who are at higher risk of recurrent stroke despite receiving standard medical treatment? Is DPR more accurate than traditional angiographic stenosis measurements for assessing the functional severity of intracranial arterial disease? Participants will undergo routine digital subtraction angiography as part of their clinical evaluation. Their angiographic images will be analyzed using a computational method to estimate blood flow impairment, and they will be followed for up to 12 months to monitor stroke related outcomes.

Detailed description

Intracranial atherosclerotic stenosis (ICAS) is a major cause of ischemic stroke, representing \ 15% of cases in Western populations and up to 46.6% in Asia. Even with intensive medical therapy, annual stroke recurrence remains high (7.2-20%), prompting exploration of additional treatment strategies. Early trials such as SAMMPRIS and VISSIT suggested worse outcomes with stenting compared with aggressive medical therapy, largely due to concerns over operator experience, patient selection, and timing. Subsequent analyses showed that patients with hemodynamic compromise-such as watershed infarction and poor collaterals-have recurrence rates up to 37%, underscoring the central role of impaired cerebral perfusion. Although more recent studies (CASSISS, BASIS) demonstrated that endovascular therapy may be safe and effective in carefully selected patients, current ICAS assessment relies primarily on stenosis severity, which correlates only weakly with true hemodynamic impairment and is insufficient for accurate risk stratification. Because symptoms arise principally from reduced perfusion, physiologic evaluation is essential. Fractional flow reserve (FFR) is the gold standard for assessing coronary lesion significance and guiding intervention through translesional pressure gradients. Attempts to translate this approach to ICAS using invasive pressure wires have shown feasibility but remain limited by anatomical differences, lack of dedicated devices, procedural risks, and unclear outcome thresholds. Our prior work demonstrated that intracranial translesional pressure gradients correlate strongly with cerebral blood flow in both animal models and clinical settings, validating hemodynamic relevance. To overcome the limitations of invasive measurements, the present study seeks to develop and evaluate a noninvasive, angiography-derived pressure ratio (DPR) using routine digital subtraction angiography. This method allows physiologic assessment without pressure wires and may reduce procedural risk. The objectives of this project are to establish a computational DPR technique, determine its association with clinical outcomes, identify a hemodynamic threshold for stroke-risk stratification, and validate its performance in a prospective multicenter cohort. By enabling early identification of high-risk ICAS patients who may respond poorly to medical therapy, DPR has the potential to improve treatment selection and outcomes, ultimately advancing strategies for stroke prevention.

Interventions

Dual antiplatelet treatment and management of vascular risk factors, in accordance with AHA/ASA guidelines

Sponsors

Suining Hospital of Traditional Chinese Medicine
CollaboratorUNKNOWN
Nanfang Hospital, Southern Medical University
CollaboratorOTHER
The First Affiliated Hospital of Zhengzhou University
CollaboratorOTHER
Xuanwu Jinan Hospital
CollaboratorUNKNOWN
The First Affiliated Hospital of University of Science and Technology of China
CollaboratorOTHER
First Affiliated Hospital of Chongqing Medical University
CollaboratorOTHER
Jiangmen Central Hospital
CollaboratorOTHER
Hebi People's Hospital
CollaboratorUNKNOWN
Shanghai Sixth People's Hospital Anhui Branch
CollaboratorUNKNOWN
Xuanwu Hospital, Beijing
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Patients with intracranial atherosclerotic stenosis (ICAS) of the anterior circulation. 2. History of an ischemic cerebrovascular event related to the target artery within the past 12 months, including ischemic stroke involving less than one-half of the middle cerebral artery territory or transient ischemic attack. 3. Age between 18 and 80 years. 4. Stenosis severity of 50% to 99% identified by transcranial Doppler ultrasound, CT angiography, or MR angiography, and confirmed as 50% to 99% stenosis on digital subtraction angiography. 5. Good compliance, willingness to sign written informed consent, and ability to complete follow-up.

Exclusion criteria

1. Non-atherosclerotic intracranial stenosis such as moyamoya disease, vasculitis, or arterial dissection. 2. Coexisting ipsilateral arterial stenosis greater than 50% other than the target lesion. 3. Large territorial infarction on MRI DWI involving at least one-half of the MCA territory with a modified Rankin Scale score greater than 3. 4. Contraindications to the use of antiplatelet agents or statins. 5. Inability to undergo DSA because of severe iodinated contrast allergy, severe hyperthyroidism, severe coagulation abnormalities with high bleeding risk, or severe cardiac, hepatic, or renal insufficiency. 6. Pregnant or breastfeeding women.

Design outcomes

Primary

MeasureTime frameDescription
ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment.Baseline to 12 months (±2 months)the number of participants who suffer from ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment.

Secondary

MeasureTime frameDescription
transient ischemic attack (TIA) or ischemic stroke in the qualifying artery territory within 1 yearBaseline to 12 months (±2 months)the number of participants who suffer from transient ischemic attack (TIA) or ischemic stroke in the qualifying artery territory within 1 year after enrollment.
TIA related to ischemia in the qualifying artery territory within 1 yearBaseline to 12 months (±2 months)the number of participants who suffer from TIA related to ischemia in the qualifying artery territory within 1 year
any stroke/TIA/ death within 1 yearBaseline to 12 months (±2 months)the number of participants who suffer from any stroke/TIA/ death within 1 year
hemodynamic ischemic stroke in the qualifying artery territory within 1 yearBaseline to 12 months (±2 months)the number of participants who suffer from hemodynamic ischemic stroke in the qualifying artery territory within 1 year
embolic stroke within in the qualifying artery territory 1 yearBaseline to 12 months (±2 months)the number of participants who suffer from embolic stroke within in the qualifying artery territory 1 year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026